Biotechnology industries
LifeCycle Pharma A/S, a privately owned biotechnology company, has completed a EUR 15 million private placement, led by Alta Partners, a US-based life science investor. The funding will be used to advance the company's main projects from the clinical phase to registration, including reformulated versions of fenofibrate
Biotechnology industries
In a significant step towards developing innovative treatments for life-threatening diseases, InNexus Biotechnology, Inc. has partnered with the renowned Mayo Clinic in a multiyear collaborative research agreement. This collaboration aims to drive the leading science of monoclonal antibody development, focusing on cancer, cardiovascular disease, and other challenging conditions. By combining
Biotechnology industries
Pennsylvania Governor Edward G. Rendell announced the sixth grant from the $5 million Manufacturing Sector Incumbent Worker Training Program, allocating $400,000 to upgrade the skills of workers in biotech companies in southeast Pennsylvania. The investment aims to secure the biotech industry in the region by ensuring workers are among
Biotechnology industries
RheoGene Inc. has revolutionized the field of gene-targeting enzymes with the introduction of AttSite Recombinases, a novel platform that enables site-specific DNA modification in a broad range of organisms. This innovative technology has far-reaching applications in functional genomics, transgenics technology, biotherapeutic protein production, and stem cell and gene therapy. Thomas
Biotechnology industries
Biogen Idec, the world's third-largest biotechnology company, has partnered with Ciber, Inc. for a multi-year contract to provide day-to-day maintenance and application development services for its Lotus Notes application. The partnership leverages Ciber's global delivery model, offering a cost-effective and high-quality delivery option. The contract marks
Biotechnology industries
Biotie Therapies Corp. aims to bolster its financial standing by offering new shares primarily to existing shareholders, option right holders, and convertible loan holders, with the hope of raising up to approximately EUR 9 million in new capital. The proposed share capital increase involves issuing a maximum of 12 million
Biotechnology industries
ViroLogic, Inc., a biotechnology company, has achieved a record revenue of $10 million in the first quarter of 2005, marking a significant increase from the $9 million revenue reported in the same quarter of 2004. The company's HIV patient testing products generated $5.9 million in revenue, while
Biotechnology industries
Vitro Diagnostics, Inc. has announced the filing of a new patent application with the United States Patent and Trademark Office, describing a method for generating beta islets from stem cells. The company's breakthrough discovery enables the creation of immortal cell lines that can be induced to form beta
Biotechnology industries
Seattle Genetics, Inc. (SGEN) has partnered with MedImmune, Inc. to develop and commercialize antibody-drug conjugate (ADC) products. Under the collaboration, MedImmune will utilize Seattle Genetics' ADC technology to target a specific tumor target and pay an upfront fee of $2.0 million. MedImmune also has the option to access
Biotechnology industries
Viventia Biotech, a biopharmaceutical company developing Armed Antibodies for cancer treatment, presented preclinical research findings in four poster presentations at the 96th American Association for Cancer Research (AACR) Annual Meeting. The company showcased its Stealth Armed Antibody product candidate, VB6-845, and Proxinium, a recombinant immunotoxin for targeting head and neck
Biotechnology industries
Sinovac Biotech Ltd. (SVA) has been experiencing significant growth in the sales of its hepatitis A vaccine, Healive, with domestic Chinese sales reaching approximately US$6.5 million for the year ended December 31, 2004, more than 2 times the sales from 2003. This growth is a testament to the
Biotechnology industries
Amazon Biotech, Inc. (AMZB), a pharmaceutical company developing a potential immunomodulator drug for HIV treatment, has announced its retention of ROI Group Associates, Inc. as its investor relations counsel, marking a significant step as the company prepares to initiate U.S.-based clinical trials. The appointment of ROI Group Associates
